From: Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time
SPM’s CN state | Allocation | Multiplicity | Cellular prevalence |
---|---|---|---|
(0,2) | q 31 | 1 | 1 |
 | q 31 | 2 | 1 |
 | q 32 | 1 | ηB/ϕ |
 | q 33 | 1 | ηC/ϕ |
(1,1) | q 31 | 1 | 1 |
 | q 32 | 1 | ηB/ϕ |
 | q 33 | 1 | ηC/ϕ |
(1,3) | q 31 | 1 | 1 |
 | q 31 | 3 | 1 |
 | q 32 | 1 | ηB/ϕ |
 | q 33 | 1 | ηC/ϕ |